Rifampicin-Trimethoprim-DDI

Modeling of published clinical Rifampicin-Trimethoprim-DDI studies for model evaluation

Repository files

Within this repository, we distribute a PK-Sim project file containing simulations of all published clinical studies used to evaluate the predictive performance of the trimethoprim model regarding the rifampicin-trimethoprim-DDI, including the respective observed data digitized from literature reports. The applied rifampicin model has been published previously [1]. For further details and documentation please refer to [2].

Version information

PK-Sim Version 8.0

Code of conduct

Everyone interacting in the Open Systems Pharmacology community (codebases, issue trackers, chat rooms, mailing lists etc...) is expected to follow the Open Systems Pharmacology code of conduct.

Contribution

We encourage contribution to the Open Systems Pharmacology community. Before getting started please read the contribution guidelines. If you are contributing code, please be familiar with the coding standard.

License

The model code is distributed under the GPLv2 License.

Reference

[1] Hanke N, Frechen S, Moj D, Britz H, Eissing T, Wendl T, Lehr T. PBPK Models for CYP3A4 and P‐gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin. CPT Pharmacometrics Syst Pharmacology 2018, 7(10):647-59.

[2] Türk D, Hanke N, Lehr T. A Physiologically-Based Pharmacokinetic Model of Trimethoprim for MATE1, OCT1, OCT2, and CYP2C8 Drug–Drug–Gene Interaction Predictions. Pharmaceutics 2020, 12(11), 1074.